Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2021; 18(01): 27-29
DOI: 10.1055/a-1367-3888
Aktuell diskutiert

Senology at the time of the coronavirus – What we did or should learn from the COVID-19 pandemic

Olivia Pagani
  Interdisciplinary Cancer Service, Hopital Riviera-Chablais, Rennaz, Geneva University Hospitals, European School of Oncology, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

The COVID-19 pandemic has greatly changed and challenged, all over the world, the way breast cancer, and not only, is managed. Several guidelines [1] [2] [3] [4] have been published to help navigating these difficult times, when health resources have been blocked or shifted from screening and treatments to emergency units and infectious disease departments.



Publication History

Article published online:
10 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dietz JR, Moran MS, Isakoff SJ. et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020; 181 (03) 487-497
    CrossrefPubMedGoogle Scholar
  • 2 Curigliano G, Cardoso MJ, Poortmans P. et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast 2020; 52: 8-16
    CrossrefPubMedGoogle Scholar
  • 3 de Azambuja E, Trapani D, Loibl S. et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open 2020; 5 (Suppl. 03) DOI: 10.1136/esmoopen-2020-000793.
    CrossrefPubMedGoogle Scholar
  • 4 Battisti NML, Mislang AR, Cooper L. et al. Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. J Geriatr Oncol 2020; 11 (08) 1190-1198
    CrossrefPubMedGoogle Scholar
  • 5 Kuderer NM, Choueiri TK, Shah DP. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet 2020; 395: 1907-1918
    CrossrefPubMedGoogle Scholar
  • 6 Patt D, Gordan L, Diaz M. et al. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform 2020; 4: 1059-1071
    CrossrefPubMedGoogle Scholar
  • 7 Moraliyage H, De Silva D, Ranasinghe W. et al. Cancer in Lockdown: Impact of the COVID-19 Pandemic on Patients with Cancer. Oncologist 2020; DOI: 10.1002/onco.13604.
    CrossrefPubMedGoogle Scholar
  • 8 Freer PE. The Impact of the COVID-19 Pandemic on Breast Imaging. Radiol Clin North Am 2021; 59 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 9 Vigliar E, Cepurnaite R, Alcaraz-Mateos E. et al. Global impact of the COVID-19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathol 2020; 128 (12) 885-894
    CrossrefPubMedGoogle Scholar
  • 10 Benusiglio PR, Korenbaum C, Vibert R. et al. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic. Eur J Med Genet 2020; 63 (12) 104098
    CrossrefPubMedGoogle Scholar
  • 11 Johnson BA, Waddimba AC, Ogola GO. et al. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic. Am J Surg 2020; DOI: 10.1016/j.amjsurg.2020.12.015.
    CrossrefPubMedGoogle Scholar
  • 12 Romics L, Doughty J, Stallard S. et al. A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland. Breast 2020; 55: 1-6
    CrossrefPubMedGoogle Scholar
  • 13 Jallali N, Hunter JE, Henry FP. et al. The feasibility and safety of immediate breast reconstruction in the COVID-19 era. J Plast Reconstr Aesthet Surg 2020; 73 (11) 1917-1923
    CrossrefPubMedGoogle Scholar
  • 14 Wong W, Brieva C, May M. et al. A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapy. Semin Oncol 2020; DOI: 10.1053/j.seminoncol.2020.11.001.
    CrossrefPubMedGoogle Scholar
  • 15 Bersanelli M, Giannarelli D, De Giorgi U. et al. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Ther Adv Med Oncol 2020; 12: 1758835920968463
    CrossrefPubMedGoogle Scholar
  • 16 Nichetti F, Bini M, Ambrosini M. et al. COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. ESMO Open 2020; 5 (Suppl. 03) DOI: 10.1136/esmoopen-2020-000883.
    CrossrefPubMedGoogle Scholar
  • 17 Zhang B, Xie R, Hubert SM. et al. Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19. Front Oncol 2020; 10: 570130
    CrossrefPubMedGoogle Scholar
  • 18 Fujiwara Y, Sato Y, Wang X. et al. Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer Hospital. Cancer Cell 2020; 38 (05) 609-610
    CrossrefPubMedGoogle Scholar
  • 19 Arpino G, De Angelis C, De Placido P. et al. Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. ESMO Open 2020; 5 (05) DOI: 10.1136/esmoopen-2020-000885.
    CrossrefPubMedGoogle Scholar
  • 20 Rocco N, Montagna G, Di Micco R. et al. The Impact of the COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future Perspectives. Oncologist 2020; DOI: 10.1002/onco.13560.
    CrossrefPubMedGoogle Scholar
  • 21 Raghavan D, Tan AR, Story ES. et al. Management changes for patients with endocrine-related cancers in the COVID-19 pandemic. Endocr Relat Cancer 2020; 27 (09) R357-R374
    CrossrefPubMedGoogle Scholar
  • 22 Specht M, Sobti N, Rosado N. et al. High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis. Breast Cancer Res Treat 2020; 182 (03) 679-688
    CrossrefPubMedGoogle Scholar
  • 23 Koch CA, Lee G, Liu ZA. et al. Rapid Adaptation of Breast Radiation Therapy Use During the Coronavirus Disease 2019 Pandemic at a Large Academic Cancer Center in Canada. Adv Radiat Oncol 2020; 5 (04) 749-756
    CrossrefPubMedGoogle Scholar
  • 24 Fedele P, Sanna V, Fancellu A. et al. De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?. Crit Rev Oncol Hematol 2020; 157: 103148
    CrossrefPubMedGoogle Scholar
  • 25 Fedele P, Ferro A, Sanna V. et al. Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. J Chemother 2020; 1-6
    CrossrefPubMedGoogle Scholar
  • 26 Griffiths EA, Alwan LM, Bachiashvili K. et al. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw 2020; 1-4
    PubMedGoogle Scholar
  • 27 Schuster-Bruce AT, Middleton HAR, Macpherson C. et al. Patient satisfaction with nurse-led end of treatment telephone consultation for breast cancer during COVID-19 pandemic. Breast J 2020; DOI: 10.1111/tbj.14034.
    CrossrefPubMedGoogle Scholar
  • 28 Sonagli M, Cagnacci Neto R, Leite FPM. et al. The use of telemedicine to maintain breast cancer follow-up and surveillance during the COVID-19 pandemic. J Surg Oncol 2020; DOI: 10.1002/jso.26327.
    CrossrefPubMedGoogle Scholar
  • 29 Zimmerman BS, Seidman D, Berger N. et al. Patient Perception of Telehealth Services for Breast and Gynecologic Oncology Care during the COVID-19 Pandemic: A Single Center Survey-based Study. J Breast Cancer 2020; 23 (05) 542-552
    CrossrefPubMedGoogle Scholar
  • 30 Swainston J, Chapman B, Grunfeld EA. et al. COVID-19 Lockdown and Its Adverse Impact on Psychological Health in Breast Cancer. Front Psychol 2020; 11: 2033
    CrossrefPubMedGoogle Scholar
  • 31 Papautsky EL, Hamlish T. Emotional Response of US Breast Cancer Survivors during the COVID-19 Pandemic. Cancer Invest 2021; 39 (01) 3-8
    CrossrefPubMedGoogle Scholar
  • 32 Osterman CK, Triglianos T, Winzelberg GS. et al. Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic. Support Care Cancer 2020; DOI: 10.1007/s00520-020-05744-y.
    CrossrefPubMedGoogle Scholar
  • 33 Flores S, Kurian N, Yohannan A. et al. Consequences of the COVID-19 Pandemic on Cancer Clinical Trials. Cancer Med J 2021; 4 (01) 38-43
    PubMedGoogle Scholar
  • 34 Marcum M, Kurtzweil N, Vollmer C. et al. COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspective. Cancer Med 2020; 9 (17) 6141-6146
    CrossrefPubMedGoogle Scholar
  • 35 The European Medicines Agency (EMA), Good Clinical Practice (GCP) Inspectors Working Group (GCP IWG), the Clinical Trials Facilitation and Coordination Group (CTFG, a working group of the Heads of Medicines Agency (HMA), the Clinical Trials Expert Group (CTEG, a working group of the European Commission representing Ethics Committees and National Competent Authorities (NCA)) and the European Commission (EC). Guidance on the Management of Clinical Trials during the Covid-19 (Coronavirus) Pandemic (Version 3, 28.04.2020). Im Internet (Stand: 21.01.2021): https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf
    PubMedGoogle Scholar
  • 36 U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Oncology Center of Excellence (OCE), Office of Good Clinical Practice (OGCP). FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency (März 2020, Update am 21.09.2020). Im Internet (Stand: 21.01.2020): https://irb.duhs.duke.edu/sites/irb.duhs.duke.edu/files/field/attachments/FDA%20COVID%20Sept_highlighted%20changes.pdf
    PubMedGoogle Scholar